Michael D Wendt

Summary

Affiliation: Abbott Laboratories
Country: USA

Publications

  1. ncbi request reprint Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo
    Michael D Wendt
    Cancer Research, Global Pharmaceutical R and D, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    J Med Chem 49:1165-81. 2006
  2. doi request reprint Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein-protein interaction
    Michael D Wendt
    Abbott Laboratories, Cancer Research, Global Pharmaceutical R and D, Dept R4N6, Bldg AP10 3, 100 Abbott Park Road, Abbott Park, Illinois 60064, USA 1 847 937 9305 1 847 938 1004
    Expert Opin Drug Discov 3:1123-43. 2008
  3. ncbi request reprint Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution
    Michael D Wendt
    Cancer Research and Structural Biology, Global Pharmaceutical R and D, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064 6101, USA
    J Med Chem 47:303-24. 2004
  4. ncbi request reprint Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors
    Michael D Wendt
    Cancer Research, Global Pharmaceutical R and D, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 6101, USA
    Bioorg Med Chem Lett 14:3063-8. 2004
  5. ncbi request reprint Discovery of a novel small molecule binding site of human survivin
    Michael D Wendt
    Cancer Research, Global Pharmaceutical R and D, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 6101, USA
    Bioorg Med Chem Lett 17:3122-9. 2007
  6. ncbi request reprint Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL
    Milan Bruncko
    Cancer Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064, USA
    J Med Chem 50:641-62. 2007
  7. doi request reprint Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins
    Cheol Min Park
    Cancer Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064, USA
    J Med Chem 51:6902-15. 2008
  8. ncbi request reprint Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties
    Milan Bruncko
    Cancer Research, Global Pharmaceutical R and D, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 6101, USA
    Bioorg Med Chem Lett 15:93-8. 2005
  9. ncbi request reprint Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies
    Jeffrey R Huth
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Chem Biol Drug Des 70:1-12. 2007
  10. ncbi request reprint An inhibitor of Bcl-2 family proteins induces regression of solid tumours
    Tilman Oltersdorf
    Idun Pharmaceuticals, 9380 Judicial Drive, San Diego, California 92121, USA
    Nature 435:677-81. 2005

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo
    Michael D Wendt
    Cancer Research, Global Pharmaceutical R and D, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    J Med Chem 49:1165-81. 2006
    ..However, consistent with the proposed mechanism, 73R potentiated the activity of paclitaxel and UV irradiation in vitro and potentiated the antitumor efficacy of paclitaxel in a mouse xenograft model...
  2. doi request reprint Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein-protein interaction
    Michael D Wendt
    Abbott Laboratories, Cancer Research, Global Pharmaceutical R and D, Dept R4N6, Bldg AP10 3, 100 Abbott Park Road, Abbott Park, Illinois 60064, USA 1 847 937 9305 1 847 938 1004
    Expert Opin Drug Discov 3:1123-43. 2008
    ..The example of ABT-263 provides evidence that the larger family of PPI targets is more tractable than may have been thought...
  3. ncbi request reprint Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution
    Michael D Wendt
    Cancer Research and Structural Biology, Global Pharmaceutical R and D, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064 6101, USA
    J Med Chem 47:303-24. 2004
    ..In combination with our exploration of 8-substitution patterns, we have identified a number of novel binding interactions for uPA inhibitors...
  4. ncbi request reprint Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors
    Michael D Wendt
    Cancer Research, Global Pharmaceutical R and D, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 6101, USA
    Bioorg Med Chem Lett 14:3063-8. 2004
    ..Combination of these substituents or of previously described NH-linked heteroaromatic rings with 6-phenyl amide substituents provided further enhancements to potency and selectivity...
  5. ncbi request reprint Discovery of a novel small molecule binding site of human survivin
    Michael D Wendt
    Cancer Research, Global Pharmaceutical R and D, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 6101, USA
    Bioorg Med Chem Lett 17:3122-9. 2007
    ....
  6. ncbi request reprint Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL
    Milan Bruncko
    Cancer Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064, USA
    J Med Chem 50:641-62. 2007
    ..Compound 2 demonstrated single agent efficacy against human follicular lymphoma cell lines that overexpress Bcl-2, and efficacy in a murine xenograft model of lymphoma when given both as a single agent and in combination with etoposide...
  7. doi request reprint Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins
    Cheol Min Park
    Cancer Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064, USA
    J Med Chem 51:6902-15. 2008
    ..Compound 2 is currently in multiple phase 1 clinical trials in patients with small cell lung cancer and hematological malignancies...
  8. ncbi request reprint Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties
    Milan Bruncko
    Cancer Research, Global Pharmaceutical R and D, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 6101, USA
    Bioorg Med Chem Lett 15:93-8. 2005
    ..These compounds possess excellent binding activities and selectivities with significantly improved pharmacokinetic profiles versus previously described amide-linked inhibitors...
  9. ncbi request reprint Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies
    Jeffrey R Huth
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Chem Biol Drug Des 70:1-12. 2007
    ..Thus, ample opportunities exist to use these lead series in the development of clinically useful HSP90 inhibitors for the treatment of cancers...
  10. ncbi request reprint An inhibitor of Bcl-2 family proteins induces regression of solid tumours
    Tilman Oltersdorf
    Idun Pharmaceuticals, 9380 Judicial Drive, San Diego, California 92121, USA
    Nature 435:677-81. 2005
    ....
  11. ncbi request reprint An NMR method for assigning relative stereochemistry to beta-hydroxy ketones deriving from aldol reactions of methyl ketones
    William R Roush
    Department of Chemistry, University of Michigan, Ann Arbor 48109, USA
    J Org Chem 67:4284-9. 2002
    ..The stereochemistry of 54 of these compounds have been assigned by rigorous chemical methods...
  12. ncbi request reprint Studies on the synthesis of bafilomycin A(1): stereochemical aspects of the fragment assembly aldol reaction for construction of the C(13)-C25) segment
    William R Roush
    Department of Chemistry, Indiana University, Bloomington 47405, USA
    J Org Chem 67:4275-83. 2002
    ..The stereoselectivity of these reactions is also highly dependent on the protecting groups and stereochemistry of the chiral aldehyde substrates...
  13. ncbi request reprint Total synthesis of (-)-bafilomycin A(1)
    Karl A Scheidt
    Department of Chemistry, University of Michigan, Ann Arbor, Michigan 48109, USA
    J Am Chem Soc 124:6981-90. 2002
    ..Finally, all silicon protecting groups were removed by treatment of the penultimate intermediate 65 with TAS-F (tris(dimethylamino)sulfonium difluorotrimethylsilicate), thereby completing the total synthesis of (-)-bafilomycin A(1)...